Wegovy and Cancer Risk: What the Evidence Actually Shows

The thyroid signal: why it is on the label and why context matters

The cancer concern most often raised about semaglutide relates to the thyroid. In rodent studies, GLP-1 receptor agonists produced C-cell tumours (a type of medullary thyroid carcinoma) at doses far exceeding those used in humans. Because rodent and human thyroid tissue differ meaningfully in GLP-1 receptor density, regulators have not concluded that this finding transfers directly to people, but they have not dismissed it either.

The STEP clinical trial programme, which involved thousands of adults treated with semaglutide 2.4mg over up to 68 weeks, did not report a statistically significant increase in thyroid cancer cases compared with placebo. The NHS patient information for semaglutide sets out the precautionary contraindication clearly: Wegovy should not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). If either applies to you, the prescriber will not proceed, and that is the right outcome.

Post-marketing surveillance is ongoing. The Black Triangle (▼) status of Wegovy means the MHRA actively collects additional safety data beyond what clinical trials captured, and any concern that emerges from that monitoring would trigger a public communication. Nothing about thyroid or other cancers has changed the medicine's benefit-risk profile as assessed by UK regulators to date. If you want to understand the full picture, our page covering Wegovy side effects and cancer goes into this in more detail, alongside the broader side-effect picture on our Wegovy side effects page if that context is helpful.

What some evidence suggests about obesity-related cancer risk

Obesity itself is a recognised risk factor for more than a dozen cancer types, including endometrial, colorectal, breast (post-menopause), oesophageal and kidney cancers. That is an established link, not a speculative one.

Several large observational studies (not clinical trials) have found that patients treated with semaglutide had lower rates of some obesity-related cancers compared with those treated with other diabetes medicines. A frequently cited analysis published in the peer-reviewed literature covered millions of patient records and suggested associations with reduced incidence of certain cancers. Importantly, observational data cannot establish causation: patients prescribed semaglutide differ in important ways from comparison groups, and the weight loss itself, dietary changes, and other factors all confound the picture.

The honest position is that researchers are actively investigating whether GLP-1 medicines may have direct anti-tumour mechanisms, independent of weight loss. Nothing in the current evidence base supports a clinical claim that Wegovy prevents cancer; equally, nothing in the human data supports a claim that it causes it, and our page covering the risk of Wegovy sets out the regulatory view on where that uncertainty currently sits, alongside our page on Wegovy risks and the broader regulatory view on where the evidence stands. That is the position the evidence sits in right now, genuinely uncertain in some directions, reasonably reassuring in others.

When to get medical help, and how to report concerns

Wegovy's most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion. These are not cancer-related and are expected, particularly early in treatment or after a dose increase. There are a small number of symptoms that warrant prompt medical attention.

Seek urgent medical help if you notice: a lump or swelling in your neck, hoarseness or persistent difficulty swallowing (potential thyroid signals); severe, persistent abdominal pain that radiates to your back, with or without vomiting (a possible sign of pancreatitis, flagged in the MHRA's January 2026 Drug Safety Update on GLP-1 medicines); or any symptoms you cannot explain and that are new since starting treatment. These are not reasons to avoid treatment; they are reasons to have a clear plan before you start.

If you experience any suspected side effect while on Wegovy, you can report it directly through the MHRA Yellow Card scheme, patients can report, not just clinicians. Reporting genuinely helps the evidence base improve. If something worries you mid-treatment, our aftercare team is available seven days a week; you can reach us through the contact page.

How a prescriber works through this with you

The decision about whether Wegovy is suitable for you is not made by a checklist or an algorithm. At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, your medical history, any conditions, any medications, and any family history that bears on the contraindications above.

Thyroid history, a diagnosis of MEN2, previous pancreatitis, gallbladder disease: these are all covered as part of that review. If there is a genuine contraindication, the prescriber will tell you and explain why, the same conversation you would have with a GP. The difference is that it happens the same day, without a waiting list, and includes structured aftercare. Our clinical team page gives you a sense of who is reviewing your case.

If you want to read about the wider landscape of risk factors assessed before Wegovy is prescribed, or weigh up whether the benefits outweigh the risks in more detail, those pages are good places to start. For anyone ready to have that clinical conversation, you can check your eligibility through a free consultation, our prescribers discuss suitability and any safety questions as a routine part of that assessment. The pen in the fridge door is not the right first thing; the conversation is.